These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26783196)

  • 1. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
    Ikai A; Watanabe M; Sowa Y; Kishimoto M; Yanagisawa A; Fujiwara H; Otsuji E; Sakai T
    Int J Oncol; 2016 Mar; 48(3):1297-304. PubMed ID: 26783196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
    Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
    BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
    Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
    Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
    Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
    Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
    Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
    Huang CI; Huang YK; Lee HM; Chen JH; Su YC; Lin PM
    Anticancer Res; 2023 May; 43(5):1933-1941. PubMed ID: 37097665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.
    Choi SH; Hong HK; Cho YB; Lee WY; Yoo HY
    PLoS One; 2015; 10(5):e0126830. PubMed ID: 25973791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single protein encapsulated SN38 for tumor-targeting treatment.
    Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
    Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
    BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical antitumor activity of a nanoparticulate SN38.
    Al-Kasspooles MF; Williamson SK; Henry D; Howell J; Niu F; Decedue CJ; Roby KF
    Invest New Drugs; 2013 Aug; 31(4):871-80. PubMed ID: 23299391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
    Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
    Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
    Sharma A; Vatapalli R; Abdelfatah E; Wyatt McMahon K; Kerner Z; A Guzzetta A; Singh J; Zahnow C; B Baylin S; Yerram S; Hu Y; Azad N; Ahuja N
    PLoS One; 2017; 12(4):e0176139. PubMed ID: 28445481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.